Theranos (Private:THERA) allegedly voided 11.3% of all blood-test reports that it provided to customers of Walgreens (NASDAQ:WBA) stores through a yearslong partnership between the two companies.

When news broke last week that Walgreens had filed a $140M suit against Elizabeth Holmes' now-hobbled unicorn for breach of contact - details were sparse - but a public version of the complaint against Theranos has now been released.

Albertsons and Kroger (NYSE:KR) have emerged as key prospective suitors for Walgreens (NASDAQ:WBA) in its attempts to find a way to satisfy the FTC's review of the company's proposed acquisition of Rite Aid (NYSE:RAD), while CVS (NYSE:CVS) seems to have withdrawn interest, CTFN reports.

Walgreens has not yet "freshened up the package" of store selloffs that it plans to present to the FTC, according to the report, which cites an antitrust attorney, who also says that "Albertsons and Kroger are established retail players with experience in pharmacies" and that the assets they are eyeing represent "key geographic expansion for both."

In accordance of their agreement, Walgreens Boots Alliance (NASDAQ:WBA) and Rite Aid (NYSE:RAD) extend the end date of their intended merger three months to January 27, 2017. The transaction is expected to close sometime in January.

Just a negotiating tactic? Height Securities suggests that Kroger (KR+0.5%) may have intentionally leaked that they were close to stepping away from plans to buy Walgreens and Rite Aid (RAD-5.3%) stores.

The investment firm speculates that Kroger is still in the mix while it waits for a sweeter offer from Walgreen Boots Alliance (WBA-0.8%).

Rite Aid (RAD-4.5%) tumbles in early trading after the NY Post reports that Kroger (KR+0.3%) may pass on buying the 650 stores that Walgreens (WBA-1.2%) and RAD would need to sell to gain regulatory approval for their planned merger.

KR may decide not to buy because the Federal Trade Commission, now a year into its merger review, recently told the company that the stores could not be purchased and closed, with the operations moved inside the grocery stores, according to the report.

A WBA-RAD merger would create the biggest U.S. drug chain, and the FTC could sue to block the deal without a solution to the stores, but the report quotes a source as saying that both the FTC and WAG remain motivated to find a remedy.